Search results
Showing 1156 to 1170 of 7680 results
NICE is unable to make a recommendation on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy. This is because AstraZeneca did not provide an evidence submission.
Show all sections
Sections for TA750
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.
Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)
Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.
Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Bimekizumab for treating moderate to severe plaque psoriasis (TA723)
Evidence-based recommendations on bimekizumab (Bimzelx) for treating moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.
Evidence-based recommendations on abemaciclib (Verzenios) with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in adults.
NICE is unable to make a recommendation on daratumumab (Darzalex) with pomalidomide (Imnovid) and dexamethasone for treating relapsed or refractory multiple myeloma because Janssen did not provide an evidence submission.
Show all sections
Sections for TA726
Midostaurin for treating advanced systemic mastocytosis (TA728)
Evidence-based recommendations on midostaurin (Rydapt) for treating advanced systemic mastocytosis in adults.
Evidence-based recommendations on nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.
NICE is unable to make a recommendation on duvelisib (Copiktra) for treating relapsed follicular lymphoma after 2 or more systemic therapies in adults because Secura Bio has not provided an evidence submission.
Show all sections
Sections for TA717
Evidence-based recommendations on ixekizumab (Taltz) for treating axial spondyloarthritis in adults.
Secukinumab for treating non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating non-radiographic axial spondyloarthritis in adults.
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)
Evidence-based recommendations on chlormethine gel (Ledaga) for treating early-stage mycosis fungoides-type cutaneous T-cell lymphoma in adults.
Evidence-based recommendations on abiraterone (Zytiga) for newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults.
View recommendations for TA721Show all sections